Autolus Therapeutics plc
AUTLHealthcare|Biotechnology|GB
$1.28
+0.02 (+1.59%)
Tangible Book / Share
$0.21
Cash / Share
$0.76
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07053800 Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) | Lupus Nephritis | P2 | Recruiting | 35 | Open-label | Obecabtagene autoleucel |
| NCT04404660 A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | P1P2 | Active | 153 | Open-label | AUTO1 |
| NCT07053059 Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | Acute Lymphocytic Leukemia (ALL) | P2 | Recruiting | 30 | Open-label | Obecabtagene autoleucel |
| NCT07400029 A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | P2 | Recruiting | 40 | Open-label | Obecabtagene Autoleucel |
| NCT06333483 Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | P1 | Active | 16 | Open-label | Obecabtagene autoleucel (obe-cel) |
| NCT07139743 Obe-cel in Refractory Progressive Forms of Multiple Sclerosis | Progressive Multiple Sclerosis | P1 | Recruiting | 24 | Open-label | Obecabtagene autoleucel (obe-cel) |
| NCT06173518 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | P1 | Recruiting | 30 | Open-label | AUTO1 |
| NCT03289455 CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) | B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | P1P2 | Completed | 23 | Open-label | AUTO3 (CD19/22 CAR T cells |
| NCT03628612 Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma | P2 | By Invite | 500 | Open-label | AUTO CAR T cell therapy |
| NCT03287817 Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | P1P2 | Terminated | 52 | Open-label | AUTO3 |
| NCT03590574 Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | P1P2 | Terminated | 20 | Open-label | AUTO4 |
| NCT03287804 APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma | Multiple Myeloma | P1P2 | Terminated | 12 | Open-label | AUTO2 |
| NCT06799221 Expanded Access Program for OOS Obe-cel | Lymphoblastic Leukemia, Acute, Adult, B Cell ALL | AVAILABLE | — | — | Out-of-specification obecabtagene autoleucel |